Core Viewpoint - CareCloud, Inc. may need to engage a new independent registered public accounting firm if an ICFR auditor attestation is required for fiscal year 2025 due to its current audit firm's inability to perform the required services [1][2]. Group 1: Audit and Compliance - The current audit firm has indicated it lacks the capacity to perform an ICFR attestation, which is necessary if CareCloud's public float exceeds $75 million [2]. - The determination of whether an ICFR attestation is required will be based on CareCloud's public float as of June 30, 2025, with a threshold of $75 million for classification as an accelerated filer [3]. - CareCloud plans to provide an update on July 1, 2025, regarding its public float and any implications for its audit arrangements [3]. Group 2: Company Overview - CareCloud is a leader in AI-driven healthcare technology solutions, offering services that enhance financial and operational performance, streamline clinical workflows, and improve patient experiences [4]. - The company serves over 40,000 providers, focusing on reducing administrative burdens and operating costs through its suite of solutions, including revenue cycle management, practice management, electronic health records, and digital health [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly violating federal securities laws by making false and misleading statements regarding the company's business and operations [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Hims & Hers made false statements about a collaboration with Novo Nordisk that would ensure continued access to the weight-loss drug Wegovy for its subscribers [2]. - It is alleged that Hims & Hers misrepresented that Novo approved its offerings of compounded semaglutide products under a "personalization" exception [2]. - The suit contends that Hims & Hers falsely indicated that branded Wegovy would be available alongside compounded semaglutide options, thereby misleading investors about user choice [2]. - Positive statements regarding the partnership with Novo and ongoing access to Wegovy were also allegedly made, which contributed to the decline in the company's stock value [2]. Group 2: Legal Proceedings - The lawsuit was filed in the Northern District of California and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05321 (N.D. Cal.) [3]. - The class action is on behalf of all individuals who purchased Hims & Hers common stock between April 29, 2025, and June 23, 2025 [3]. Group 3: Class Member Information - Investors who acquired Hims & Hers stock during the specified class period may seek to be appointed as lead plaintiffs, with a deadline to do so by August 25, 2025 [4]. - It is noted that investors do not need to be lead plaintiffs to participate in any potential recovery from the lawsuit [5].

Core Insights - Amesite Inc. has enhanced its NurseMagic™ app to support charting in 16 languages, addressing the needs of nearly 1 million ESL nurses in the U.S. [1][2] - The company reported a 2.4x quarter-on-quarter revenue increase, driven by the rapid adoption of NurseMagic™ and improved operating efficiency [4][5] Company Developments - NurseMagic™ now supports languages including English, Chinese, Hindi, Spanish, French, Portuguese, Russian, Indonesian, German, Japanese, Korean, Turkish, Italian, Ukrainian, Dutch, and Swedish [3] - The company has launched a higher-priced enterprise tier to meet growing B2B demand for increased capacity [4] - NurseMagic™ reduces documentation time for nurses from 20 minutes to just 20 seconds, enhancing operational efficiency [5] Market Positioning - The multilingual capability of NurseMagic™ positions Amesite to capture value in both domestic and international markets, particularly among the 19.2% of U.S. nurses who speak English as a second language [2][6] - The platform serves B2B and B2C users across 50 states and 21 countries, with seamless integration into healthcare workflows [5]

Core Viewpoint - Option Care Health Inc. is set to release its second quarter results for the period ending June 30, 2025, on July 30, 2025, before market opening, followed by a conference call to discuss the results [1]. Group 1: Company Overview - Option Care Health is the largest independent provider of home and alternate site infusion services in the United States [3]. - The company employs over 8,000 team members, including more than 5,000 clinicians, dedicated to improving care standards for patients with acute and chronic conditions across all 50 states [3]. - Option Care Health aims to enhance the infusion care experience through its clinical leadership, expertise, and national scale [3]. Group 2: Conference Call Details - Participants can pre-register for the conference call through a provided link and access it via a live audio webcast available on the company's investor relations website [2]. - A replay of the conference call will be available shortly after its completion and will remain accessible for approximately 90 days [2].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has atai Life Sciences N.V. (ATAI) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.atai Life Sciences N.V. is a member of our Medical group, which includes 997 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the str ...

Investor Presentation May 2025 .头. Astrana Health Forward Looking Statements This presentation contains for ward-lookingstatements within the meacing of the Pivate Securities Lifyation Reform Att of 1985Section 274 of the Securities Aut and Section looding statements in blude any vatatements about the Company is business, financial conditibin, operating results, plans, odpectives, expectations and intentions, expansi market, our ability to successful Jr corrupted and realize the benefits of anticipated a ap ...

Virginia-based pediatric care network gains more complete picture of a child's health history, supports early interventions, and enhances patient engagementSolution helps network achieve value-based care objectivesAUSTIN, Texas, June 25, 2025 /PRNewswire/ -- Fortify Children's Health, a Virginia-based pediatric care network, is using Oracle Health Data Intelligence to enhance care for its pediatric population and more effectively manage value-based care contract performance. Using Oracle Health Data Intelli ...

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company: Dear OneMedNet Shareholders, Partners, and Family, Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enhancing ...

Strategic collaboration expands HealthLynked's focus on interoperability and digital transformation in hospital systems and EMRsNAPLES, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneer in healthcare technology and patient engagement, today announced a strategic partnership with Endlink, a healthcare data integration firm led by industry veteran Rubén Viera. This alliance underscores HealthLynked's commitment to building robust partnerships that enhance connectiv ...

Core Viewpoint - AMN Healthcare Services (AMN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on changes in earnings estimates, which are tracked through the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for AMN reflects an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Institutional Investors - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5]. - An increase in earnings estimates typically results in higher fair value for a stock, prompting institutional investors to buy or sell accordingly, which influences stock price movements [5]. Earnings Estimate Revisions for AMN - For the fiscal year ending December 2025, AMN is expected to earn $1.08 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 9.7% over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, where Zacks Rank 1 stocks have generated an average annual return of +25% since 1988 [8]. - AMN's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].